Comparative Pharmacology
Head-to-head clinical analysis: DONEPEZIL HYDROCHLORIDE versus EDROPHONIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DONEPEZIL HYDROCHLORIDE versus EDROPHONIUM CHLORIDE.
DONEPEZIL HYDROCHLORIDE vs EDROPHONIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibitor of acetylcholinesterase, increasing acetylcholine concentration in the synaptic cleft of the central nervous system.
Inhibits acetylcholinesterase, prolonging acetylcholine action at neuromuscular junction and autonomic ganglia.
Alzheimer's disease: Initial 5 mg orally once daily at bedtime for 4-6 weeks, increase to 10 mg once daily. Maximum dose 10 mg/day.
10 mg IV bolus, may repeat up to total 10 mg. For myasthenia gravis diagnosis: 2 mg IV test dose, then 8 mg IV if no reaction after 45 seconds.
None Documented
None Documented
Terminal elimination half-life approximately 70 hours (range 50-100 hours), allowing once-daily dosing; steady-state reached in 14-21 days
Terminal elimination half-life is 1.5-2 hours; in anephric patients, half-life may be prolonged up to 6-8 hours, requiring dose adjustment.
Renal (26% unchanged), fecal (57%, primarily as metabolites via biliary excretion)
Primarily renal excretion as unchanged drug (approximately 70-80% within 4 hours); minor biliary/fecal elimination accounts for <10%.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor